Abstract
Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the spine and sacroiliac joint and rarely the kidneys. This study aimed to define the clinical and histological features and biology of renal disease in AS. We reviewed the medical records of 681 patients diagnosed with AS from November 2008 to November 2009. Baseline characteristics and laboratory and urinalysis results were reviewed. We identified patients with proteinuria or hematuria and analyzed their risk factors. After providing informed consent, 6 patients underwent a renal biopsy to determine the cause of proteinuria or hematuria. Of the 681 enrolled patients, 547 were men and 134 were women; 81 % were HLA B27 positive, and 8 % had abnormal urinalysis findings (proteinuria, 5.9 %; hematuria, 2.8 %; both, 0.7 %). Incidences of peripheral arthritis and uveitis were 29 % and 18.6 %, respectively. Immunoglobulin (Ig)A and uric acid levels were significantly different between patients with and without proteinuria. Erythrocyte sedimentation rate (ESR), total cholesterol, creatinine, and C-reactive protein (CRP) levels were not statistically significantly different between the 2 groups nor were there any significant differences in IgA, uric acid, ESR, total cholesterol, creatinine, and CRP levels between patients with and without hematuria. Six patients who had >1 g/day proteinuria underwent a renal biopsy; 2 were diagnosed with IgA nephropathy, 1 with amyloidosis, and 3 with non-specific glomerulonephropathy. In the amyloidosis patient, severe proteinuria was the dominant feature. For patients with renal amyloidosis and other forms of glomerulonephritis who initially had normal creatinine levels, tumor necrosis factor (TNF)-alpha blocker therapy resolved proteinuria, but this was not the case for patients with initial renal insufficiency. Renal involvement is not a rare complication of AS, and prognoses differ depending on kidney pathology. Serum levels of uric acid and IgA may predict renal involvement in AS. In cases where abnormal urine sediment is identified, renal biopsy is required to determine prognosis and decide the treatment protocol. Baseline serum creatinine level is important for predicting treatment response.
Similar content being viewed by others
References
Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A (2002) Ankylosing spondylitis: an overview. Ann Rheum Dis 61(suppl 3):iii8–iii18
Lawrence RC, Helmick CG, Arnett FC et al (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthr Rheum 41:778–799
Khan MA (1995) HLA-B27 and its subtypes in world populations. Curr Opin Rheumatol 7:263–269
Braun J, Bollow M, Remlinger G et al (1998) Prevalence of spondyloarthropathies in HLA-B27 positive and negative blood donors. Arthr Rheum 41:58–67
Ng SC, Liao Z, Yu DT et al (2007) Epidemiology of spondyloarthritis in the People’s Republic of China: review of the literature and commentary. Semin Arthr Rheum 37:39–47
Helmick CG, Felson DT, Lawrence RC et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthr Rheum 58:15–25
El Maghraoui A (2004) Ankylosing spondylitis. Press Med 33:1459–1464
Elewaut D, Matucci-Cerini M (2009) Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology(Oxford) 48:1029–1035
El Maghraoui A (2011) Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med 22:554–560 (Review)
Vilar MJP, Cury SE, Ferraz MB, Sesso R, Atra E (1997) Renal abnormalities in ankylosing spondylitis. Scand J Rheumatol 26:19–23
Nabokov AV, Shabunin MA, Smirnov AV (1996) Renal involvement in ankylosing spondylitis (Bechterew’s disease). Nephrol Dial Transpl 11:1172–1175
Strobel ES, Fritschka E (1998) Reanl diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Clin Rheumatol 17:524–530
Singh G, Kumari N, Aggarwal A, Krishnani N, Misra R (2007) Prevalence of subclinical amyloidosis in ankylosing spondylitis. J Rheumatol 34:371–373
Lehtinen K (1993) Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 52:174–176
Kobak S, Oksel F, Kabasakal Y, Doganavsargil E (2007) Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients. Clin Rheumatol 26:2191–2194
Acknowledgments
This study was funded by the program of the Kyung Hee University for the young professor in 20071400.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, SH., Lee, E.J., Chung, S.W. et al. Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker. Rheumatol Int 33, 1689–1692 (2013). https://doi.org/10.1007/s00296-012-2624-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-012-2624-9